Skip to main content
Figure 1 | Trials

Figure 1

From: The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury

Figure 1

CONSORT Flowchart. Patients who withdrew from the trial and for whom final outcome measurements (GCS, HIREOS and DRS) were obtained, but earlier than scheduled, are classified as having discontinued the trial. Patients who withdrew from the trial without completing their final outcome measurements are classified as lost to follow up. Individuals who were lost to follow up do not contribute to the analyses; those who discontinued the trial contribute to this intention to treat analysis if data were available.

Back to article page

Trials

ISSN: 1745-6215